Lipids in critical care medicine

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 85, Issue 5, 2011, Pages 267-273

  Ott, Juliane ^a   Hiesgen, Christopher ^a   Mayer, Konstantin ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Critically ill patients; Enteral nutrition; Fish oil; Parenteral nutrition; Resolvin; Sepsis

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; FATTY ACID DERIVATIVE; FISH OIL; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; LIPID; LIPID EMULSION; OMEGA 3 FATTY ACID; PLACEBO; RESOLVIN; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CRITICALLY ILL PATIENT; DIET SUPPLEMENTATION; ENTERIC FEEDING; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INTENSIVE CARE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SURGICAL PATIENT; TREATMENT OUTCOME;

ACUTE LUNG INJURY; ANIMALS; CRITICAL CARE; CRITICAL ILLNESS; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ENTERAL NUTRITION; FATTY ACIDS, OMEGA-6; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LENGTH OF STAY; SEPSIS;

ANIMALIA;

EID: 80053610862     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2011.04.011     Document Type: Article

References (74)

1. Peterson J., et al. Fatty acid control of lipoprotein lipase: a link between energy metabolism and lipid transport. Proc. Natl. Acad. Sci. USA 1990, 87(3):909-913.
2. Jaume J.C., et al. Extremely low doses of heparin release lipase activity into the plasma and can thereby cause artifactual elevations in the serum-free thyroxine concentration as measured by equilibrium dialysis. Thyroid 1996, 6(2):79-83.
3. Weissman C. The metabolic response to stress: an overview and update. Anesthesiology 1990, 73(2):308-327.
4. Rustan A.C., Hustvedt B.E., Drevon C.A. Postprandial decrease in plasma unesterified fatty acids during n-3 fatty acid feeding is not caused by accumulation of fatty acids in adipose tissue. Biochim. Biophys. Acta 1998, 1390(3):245-257.
5. Lovegrove J.A., et al. Use of manufactured foods enriched with fish oils as a means of increasing long-chain n-3 polyunsaturated fatty acid intake. Br. J. Nutr. 1997, 78(2):223-236.
6. Mayer K., et al. Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Med. 2003, 29(9):1472-1481.
7. Abbey M., et al. Effect of fish oil on lipoproteins, lecithin:cholesterol acyltransferase, and lipid transfer protein activity in humans. Arteriosclerosis 1990, 10(1):85-94.
8. Qi K., et al. Omega-3 triglycerides modify blood clearance and tissue targeting pathways of lipid emulsions. Biochemistry 2002, 41(9):3119-3127.
9. Ton M.N., et al. In vivo and in vitro properties of an intravenous lipid emulsion containing only medium chain and fish oil triglycerides. Clin. Nutr. 2005, 24(4):492-501.
10. Sijben J.W., Calder P.C. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Proc. Nutr. Soc. 2007, 66(2):237-259.
11. Mayer K., Seeger W. Fish oil in critical illness. Curr. Opin. Clin. Nutr. Metab. Care 2008, 11(2):121-127.
12. Calder P.C. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 2003, 38(4):343-352.
13. Simopoulos A.P. Evolutionary aspects of omega-3 fatty acids in the food supply. Prostaglandins Leukot Essent Fatty Acids 1999, 60(5-6):421-429.
14. Serhan C.N. Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. J. Thromb. Haemost. 2009, 7(Suppl 1):44-48.
15. Prescott S.M., Stenson W.F. Fish oil fix. Nat. Med. 2005, 11(6):596-598.
16. Sun Y.P., et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem. 2007, 282(13):9323-9334.
17. Spite M., et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009, 461(7268):1287-1291.
18. Hasturk H., et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 2007, 179(10):7021-7029.
19. Flower R.J., Perretti M. Controlling inflammation: a fat chance?. J. Exp. Med. 2005, 201(5):671-674.
20. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008, 8(5):349-361.
21. Bannenberg G.L., et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 2005, 174(7):4345-4355.
22. Arita M., et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 2005, 201(5):713-722.
23. Schwab J.M., et al. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007, 447(7146):869-874.
24. Seki H., et al. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J. Immunol. 2009, 184(2):836-843.
25. Haworth O., Levy B.D. Endogenous lipid mediators in the resolution of airway inflammation. Eur. Respir. J. 2007, 30(5):980-992.
26. Levy B.D., et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J. Immunol. 2007, 178(1):496-502.
27. Connor K.M., et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 2007, 13(7):868-873.
28. Tian H., et al. Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: biosynthesis and mechanisms of anti-inflammatory actions. Invest. Ophthalmol. Vis. Sci. 2009, 50(8):3613-3620.
29. Heller A.R., et al. Impact of n-3 fatty acid supplemented parenteral nutrition on haemostasis patterns after major abdominal surgery. Br. J. Nutr. 2002, 87(Suppl 1):S95-S101.
30. Heller A.R., et al. Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients. Int. J. Cancer 2004, 111(4):611-616.
31. Antebi H., et al. Liver function and plasma antioxidant status in intensive care unit patients requiring total parenteral nutrition: comparison of 2 fat emulsions. J. Parenter. Enteral. Nutr. 2004, 28(3):142-148.
32. Grimm H., et al. Improved fatty acid and leukotriene pattern with a novel lipid emulsion in surgical patients. Eur. J. Nutr. 2006, 45(1):55-60.
33. Berger M.M., Tappy L., Revelly J.P., et al. Fish oil after abdominal aorta aneurysm surgery. Eur. J. Clin. Nutr. 2008, 62:1116-1122.
34. Pluess T.T., et al. Intravenous fish oil blunts the physiological response to endotoxin in healthy subjects. Intensive Care Med. 2007, 33(5):789-797.
35. Tsekos E., et al. Perioperative administration of parenteral fish oil supplements in a routine clinical setting improves patient outcome after major abdominal surgery. Clin. Nutr. 2004, 23(3):325-330.
36. Wichmann M.W., et al. Evaluation of clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipoplus, MLF541): data from a prospective, randomized, multicenter trial. Crit. Care Med. 2007, 35(3):700-706.
37. Mertes N., et al. Safety and efficacy of a new parenteral lipid emulsion (SMOFlipid) in surgical patients: a randomized, double-blind, multicenter study. Ann. Nutr. Metab. 2006, 50(3):253-259.
38. Heyland D.K., et al. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 2001, 286(8):944-953.
39. Heys S.D., et al. Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials. Ann. Surg. 1999, 229(4):467-477.
40. Chen B., et al. Safety and efficacy of fish oil-enriched parenteral nutrition regimen on postoperative patients undergoing major abdominal surgery: a meta-analysis of randomized controlled trials. J. Parenter. Enteral. Nutr. 2010, 34(4):387-394.
41. Weimann A., et al. ESPEN Guidelines on Enteral Nutrition: surgery including organ transplantation. Clin. Nutr. 2006, 25(2):224-244.
42. Bernard G.R., et al. The American-European consensus conference ARDS. definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am. J. Respir. Crit. Care Med. 1994, 149(3 Pt 1):818-824.
43. Grimminger F., et al. Differential influence of arachidonic vs. eicosapentaenoic acid on experimental pulmonary hypertension. Am. J. Physiol. 1995, 268(6 Pt 2):H2252-H2259.
44. Grimminger F., et al. Impact of arachidonic versus eicosapentaenoic acid on exotonin-induced lung vascular leakage: relation to 4-series versus 5-series leukotriene generation. Am. J. Respir. Crit. Care Med. 1997, 155(2):513-519.
45. Grimminger F., et al. Differential vasoconstrictor potencies of free fatty acids in the lung vasculature: 2-versus 3-series prostanoid generation. J. Pharmacol. Exp. Ther. 1993, 267(1):259-265.
46. Kelbel I., et al. Effects of Parenteral Application of Fish Oil versus Soy Oil Emulsions on Bacterial Clearance Functions. Infusions Ther. Transfusions Med 1999, 26(4):226-232.
47. Gadek J.E., et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. enteral nutrition in ARDS study group. Crit. Care Med. 1999, 27(8):1409-1420.
48. Singer P., et al. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. Crit. Care Med. 2006, 34(4):1033-1038.
49. Pontes-Arruda A., et al. The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data. J. Parenter. Enteral. Nutr. 2008, 32(6):596-605.
50. Pacht E.R., et al. Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. Crit. Care Med. 2003, 31(2):491-500.
51. Barbosa V.M., et al. Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory markers, and clinical outcomes in septic patients: a randomized, controlled clinical trial. Crit. Care 2010, 14(1):R5.
52. Stapleton R.D., et al. A phase ii, randomized, double-blind, placebo-controlled trial of fish oil (eicosapentaenoic acid and docosahexanoic acid) on lung and systemic inflammation in patients with acute lung injury. Am. J. Respir. Crit Care Med. 2009, 179:A2169.
53. Rice T.W. Final results of omega-3 fatty acids versus control in ALI (OMEGA) trial. Am. J. Respi.r Crit. Care Med. 2009, 179. Oral Presentation.
54. Angus D.C., Wax R.S. Epidemiology of sepsis: an update. Crit. Care Med. 2001, 29(7 Suppl):S109-S116.
55. Angus D.C., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001, 29(7):1303-1310.
56. Martin G.S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 2003, 348(16):1546-1554.
57. Docke W.D., et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 1997, 3(6):678-681.
58. Kox W.J., et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. a new approach: proof of principle. Arch. Intern. Med. 1997, 157(4):389-393.
59. Hotchkiss R.S., et al. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J. Immunol. 2005, 174(8):5110-5118.
60. Mascioli E., et al. Enhanced survival to endotoxin in guinea pigs fed IV fish oil emulsion. Lipids 1988, 23(6):623-625.
61. Pscheidl E.M., et al. Influence of omega-3 fatty acids on splanchnic blood flow and lactate metabolism in an endotoxemic rat model. Metabolism 1992, 41(7):698-705.
62. Pscheidl E., et al. Fish oil-supplemented parenteral diets normalize splanchnic blood flow and improve killing of translocated bacteria in a low-dose endotoxin rat model. Crit. Care Med. 2000, 28(5):1489-1496.
63. Arita M., et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA 2005, 102(21):7671-7676.
64. Bi M.H., et al. Induction of lymphocyte apoptosis in a murine model of acute lung injury-modulation by lipid emulsions. Shock 2009, (ePub).
65. Michaeli B., et al. Effects of fish oil on the neuro-endocrine responses to an endotoxin challenge in healthy volunteers. Clin. Nutr. 2007, 26(1):70-77.
66. Mayer K., et al. Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans. J. Immunol. 2003, 171(9):4837-4843.
67. Marik P.E., Zaloga G.P. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med. 2008, 34(11):1980-1990.
68. Pontes-Arruda A., Aragao A.M., Albuquerque J.D. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit. Care Med. 2006, 34(9):2325-2333.
69. Bertolini G., et al. Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial. Intensive Care Med. 2003, 29(5):834-840.
70. Wang X., et al. Omega-3 fatty acids-supplemented parenteral nutrition decreases hyperinflammatory response and attenuates systemic disease sequelae in severe acute pancreatitis: a randomized and controlled study. J. Parenter. Enteral. Nutr. 2008, 32(3):236-241.
71. Cury Boaventura M.F., et al. Toxicity of a soybean oil emulsion on human lymphocytes and neutrophils. J. Parenter Enteral. Nutr. 2006, 30(2):115-123.
72. Heller A.R., et al. Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit. Care Med. 2006, 34(4):972-979.
73. Grimm H., et al. Immunoregulation by parenteral lipids: impact of the n-3 to n-6 fatty acid ratio. J. Parenter. Enteral. Nutr. 1994, 18(5):417-421.
74. Serhan C.N. Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr. Opin. Clin. Nutr. Metab. Care 2005, 8(2):115-121.